BR112017007428A2 - composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença - Google Patents

composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença

Info

Publication number
BR112017007428A2
BR112017007428A2 BR112017007428A BR112017007428A BR112017007428A2 BR 112017007428 A2 BR112017007428 A2 BR 112017007428A2 BR 112017007428 A BR112017007428 A BR 112017007428A BR 112017007428 A BR112017007428 A BR 112017007428A BR 112017007428 A2 BR112017007428 A2 BR 112017007428A2
Authority
BR
Brazil
Prior art keywords
fatty acid
compositions
disease
ester
omega
Prior art date
Application number
BR112017007428A
Other languages
English (en)
Portuguese (pt)
Inventor
Abd Almalik Ahmed Mohammed Daak Ahmed
D Sancilio Frederick
DANIEL-ARCHIBALD Glynis
Lopez-Toledano Miguel
Thorsteinsson Thorsteinn
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017007428(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of BR112017007428A2 publication Critical patent/BR112017007428A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112017007428A 2014-10-10 2015-10-09 composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença BR112017007428A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462062652P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10
PCT/US2015/054933 WO2016057915A1 (fr) 2014-10-10 2015-10-09 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques

Publications (1)

Publication Number Publication Date
BR112017007428A2 true BR112017007428A2 (pt) 2017-12-19

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007428A BR112017007428A2 (pt) 2014-10-10 2015-10-09 composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença

Country Status (8)

Country Link
EP (1) EP3212236A1 (fr)
BR (1) BR112017007428A2 (fr)
CA (1) CA2963952C (fr)
CL (1) CL2017000867A1 (fr)
MA (1) MA40846A (fr)
MX (2) MX2017004324A (fr)
WO (1) WO2016057915A1 (fr)
ZA (1) ZA201702385B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017193563A1 (fr) * 2015-11-13 2017-11-16 深圳君圣泰生物技术有限公司 Composition, et application et préparation pharmaceutique de cette dernière
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
US11241408B2 (en) 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
IT201900007202A1 (it) * 2019-05-24 2020-11-24 Pavia Farm S R L Composizione a base di vitamine liposolubili ad elevato assorbimento enterico
MX2022001238A (es) 2019-08-13 2022-07-13 Team Foods Colombia Sa Composicion lipidica que comprende antioxidantes y polifenoles naturales como alternativa no farmacologica para el tratamiento y la prevencion de nafld.
CN115737555B (zh) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 一种千金藤素自微乳组合物、制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972063C (fr) * 2009-05-22 2019-12-17 Mochida Pharmaceutical Co., Ltd. Composition auto-emulsifiante d'acide gras .omega.3
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
EP2793867B1 (fr) * 2011-12-22 2021-01-20 Baes, Erik Capsules à libération retardée de gélatine/alginate comprenant des acides gras oméga-3, et leurs procédés et leurs utilisations
MY189576A (en) * 2012-03-30 2022-02-17 Micelle Biopharma Inc Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
EP3212236A1 (fr) 2017-09-06
MX2017004324A (es) 2017-07-04
CA2963952A1 (fr) 2016-04-14
WO2016057915A1 (fr) 2016-04-14
CL2017000867A1 (es) 2017-11-03
CA2963952C (fr) 2023-10-17
MX2020002238A (es) 2020-07-13
MA40846A (fr) 2017-09-05
ZA201702385B (en) 2020-12-23

Similar Documents

Publication Publication Date Title
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112016006926A2 (pt) composições compreendendo um conjugado de ácido quínico com ácido cafeico, usos terapêuticos e cosméticos
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
WO2014107730A3 (fr) Utilisation de conjugués d'acides gras et de niacine en vue du traitement de maladies
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
WO2014160871A3 (fr) Procédés et agents pour le traitement de la maladie d'alzheimer
TR201904514T4 (tr) Makrosiklik LRRK2 kinaz inhibitörleri.
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
BR112015019919A2 (pt) compostos bicíclicos
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112015014367A2 (pt) formulações inibidoras de lfa-1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2640 DE 10/08/2021 POR TER SIDO INDEVIDA.